Skip to main content
Erschienen in: Zeitschrift für Gerontologie und Geriatrie 4/2023

12.06.2023 | CME

Prostatakarzinom beim älteren Mann

Besonderheiten der Diagnostik und Therapie

verfasst von: PD Dr. Stephan Degener, Oliver Schmalz, Marco Tosch, Daniel Gödde, Friedrich-Carl von Rundstedt, Marc D. Piroth

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Prostatakarzinom ist das häufigste Karzinom beim Mann. Bei lokalisiertem Tumor stellen die Operation und die Strahlentherapie die Standardtherapie dar, bei niedrigem Risiko auch die aktive Überwachung. Im Fall der fortgeschrittenen/metastasierten Erkrankung erfolgt eine Androgendeprivationstherapie. Weitere Optionen sind Inhibitoren der Androgenrezeptorachse und taxanbasierte Chemotherapien. Die Vermeidung von Nebenwirkungen sollte z. B. durch Dosisanpassungen berücksichtigt werden. Neue Optionen ergeben sich durch Poly(ADP-ribose)-Polymerase(PARP)-Inhibitoren und Radioligandentherapie. Bestehende Leitlinien zum Prostatakarzinom enthalten nur wenige Empfehlungen für ältere Patienten. Jedoch sollte/sollten bei der Behandlung älterer Patienten nicht primär das chronologische Alter, sondern die psychische und physische Verfassung und die Präferenzen des Patienten berücksichtigt werden. Das geriatrische Assessment stellt ein wichtiges Instrument zur Festlegung der Behandlungsstrategie dar.
Literatur
1.
Zurück zum Zitat Zentrum für Krebsregisterdaten (2021) Krebs in Deutschalnd für 2017/2018. Robert-Koch-Institut, Berlin Zentrum für Krebsregisterdaten (2021) Krebs in Deutschalnd für 2017/2018. Robert-Koch-Institut, Berlin
3.
Zurück zum Zitat Coll PP, Korc-Grodzicki B, Ristau BT, Shahrokni A, Koshy A, Filippova OT et al (2020) Cancer prevention and screening for older adults: Part 2. Interventions to prevent and screen for breast, prostate, cervical, ovarian, and endometrial cancer. J Am Geriatr Soc 68(11):2684–2691CrossRefPubMedPubMedCentral Coll PP, Korc-Grodzicki B, Ristau BT, Shahrokni A, Koshy A, Filippova OT et al (2020) Cancer prevention and screening for older adults: Part 2. Interventions to prevent and screen for breast, prostate, cervical, ovarian, and endometrial cancer. J Am Geriatr Soc 68(11):2684–2691CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424CrossRefPubMed Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424CrossRefPubMed
5.
Zurück zum Zitat Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I et al (2014) Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 12:26CrossRefPubMedPubMedCentral Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I et al (2014) Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 12:26CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243–262CrossRefPubMed Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243–262CrossRefPubMed
7.
Zurück zum Zitat Dolezil D, Haase A, Jahnke K, Thonack J, Loffler C, Schmidt CO et al (2016) Cancer screening in the elderly: Explorative mixed methods study. Z Gerontol Geriatr 49(1):44–51CrossRefPubMed Dolezil D, Haase A, Jahnke K, Thonack J, Loffler C, Schmidt CO et al (2016) Cancer screening in the elderly: Explorative mixed methods study. Z Gerontol Geriatr 49(1):44–51CrossRefPubMed
8.
Zurück zum Zitat Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N et al (2019) Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 116:116–136CrossRefPubMed Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N et al (2019) Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 116:116–136CrossRefPubMed
9.
Zurück zum Zitat Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S et al (2015) Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 67(1):157–164CrossRefPubMed Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S et al (2015) Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 67(1):157–164CrossRefPubMed
10.
Zurück zum Zitat Gurung PMS, Wang B, Hassig S, Wood J, Ellis E, Feng C et al (2021) Oncological and functional outcomes in patients over 70 years of age treated with robotic radical prostatectomy: a propensity-matched analysis. World J Urol 39(4):1131–1140CrossRefPubMed Gurung PMS, Wang B, Hassig S, Wood J, Ellis E, Feng C et al (2021) Oncological and functional outcomes in patients over 70 years of age treated with robotic radical prostatectomy: a propensity-matched analysis. World J Urol 39(4):1131–1140CrossRefPubMed
11.
Zurück zum Zitat Mandel P, Graefen M, Michl U, Huland H, Tilki D (2015) The effect of age on functional outcomes after radical prostatectomy. Urol Oncol 33(5):203.e11–203.e18CrossRefPubMed Mandel P, Graefen M, Michl U, Huland H, Tilki D (2015) The effect of age on functional outcomes after radical prostatectomy. Urol Oncol 33(5):203.e11–203.e18CrossRefPubMed
12.
Zurück zum Zitat Leyh-Bannurah SR, Wagner C, Schuette A, Liakos N, Karagiotis T, Mendrek M et al (2022) Feasibility of robot-assisted radical prostatectomy in men at senior agee ≥75 years: perioperative, functional, and oncological outcomes of a high-volume center. Aging Male 25(1):8–16CrossRefPubMed Leyh-Bannurah SR, Wagner C, Schuette A, Liakos N, Karagiotis T, Mendrek M et al (2022) Feasibility of robot-assisted radical prostatectomy in men at senior agee ≥75 years: perioperative, functional, and oncological outcomes of a high-volume center. Aging Male 25(1):8–16CrossRefPubMed
13.
Zurück zum Zitat Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H et al (2021) NCCN guidelines insights: prostate cancer, version 1.2021. J Natl Compr Canc Netw 19(2):134–143CrossRefPubMed Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H et al (2021) NCCN guidelines insights: prostate cancer, version 1.2021. J Natl Compr Canc Netw 19(2):134–143CrossRefPubMed
14.
Zurück zum Zitat NIH (2021) Prostate cancer: diagnosis and management. Prostate cancer: diagnosis and management. National Institute for Health and Care Excellence: Guidelines NIH (2021) Prostate cancer: diagnosis and management. Prostate cancer: diagnosis and management. National Institute for Health and Care Excellence: Guidelines
15.
Zurück zum Zitat Okonogi N, Katoh H, Kawamura H, Tamaki T, Kaminuma T, Murata K et al (2015) Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age. J Radiat Res 56(6):889–896CrossRefPubMedPubMedCentral Okonogi N, Katoh H, Kawamura H, Tamaki T, Kaminuma T, Murata K et al (2015) Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age. J Radiat Res 56(6):889–896CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N et al (2018) Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World J Urol 36(1):7–13CrossRefPubMed Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N et al (2018) Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World J Urol 36(1):7–13CrossRefPubMed
17.
Zurück zum Zitat Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D et al (2020) Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations. Eur Urol Focus 6(2):231–234CrossRefPubMed Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D et al (2020) Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations. Eur Urol Focus 6(2):231–234CrossRefPubMed
18.
Zurück zum Zitat Tremeau L, Mottet N (2022) Management of biochemical recurrence of prostate cancer after curative treatment: a focus on older patients. Drugs Aging 39(9):685–694CrossRefPubMed Tremeau L, Mottet N (2022) Management of biochemical recurrence of prostate cancer after curative treatment: a focus on older patients. Drugs Aging 39(9):685–694CrossRefPubMed
19.
Zurück zum Zitat Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263–282CrossRefPubMed Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263–282CrossRefPubMed
20.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed
21.
Zurück zum Zitat Van Poppel H, Klotz L (2012) Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 19(7):594–601CrossRefPubMed Van Poppel H, Klotz L (2012) Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 19(7):594–601CrossRefPubMed
22.
Zurück zum Zitat Boukovala M, Spetsieris N, Efstathiou E (2019) Systemic treatment of prostate cancer in elderly patients: current role and safety considerations of androgen-targeting strategies. Drugs Aging 36(8):701–717CrossRefPubMed Boukovala M, Spetsieris N, Efstathiou E (2019) Systemic treatment of prostate cancer in elderly patients: current role and safety considerations of androgen-targeting strategies. Drugs Aging 36(8):701–717CrossRefPubMed
23.
Zurück zum Zitat Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS et al (2015) Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol 193(4):1226–1231CrossRefPubMed Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS et al (2015) Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol 193(4):1226–1231CrossRefPubMed
24.
Zurück zum Zitat Fallah J, Zhang L, Amatya A, Gong Y, King-Kallimanis B, Bhatnagar V et al (2021) Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Lancet Oncol 22(9):1230–1239CrossRefPubMed Fallah J, Zhang L, Amatya A, Gong Y, King-Kallimanis B, Bhatnagar V et al (2021) Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Lancet Oncol 22(9):1230–1239CrossRefPubMed
25.
Zurück zum Zitat Soleimani M, Zou K, Sunderland K, Struss W, Eigl BJ, Nappi L et al (2021) Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. Eur J Cancer 152:215–222CrossRefPubMed Soleimani M, Zou K, Sunderland K, Struss W, Eigl BJ, Nappi L et al (2021) Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. Eur J Cancer 152:215–222CrossRefPubMed
26.
Zurück zum Zitat Batra A, Marchioni M, Hashmi AZ, Lonergan PE, Morgans AK, Nead KT et al (2021) Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. J Geriatr Oncol 12(5):687–695CrossRefPubMed Batra A, Marchioni M, Hashmi AZ, Lonergan PE, Morgans AK, Nead KT et al (2021) Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. J Geriatr Oncol 12(5):687–695CrossRefPubMed
27.
Zurück zum Zitat Alibhai SMH, Breunis H, Hansen AR, Gregg R, Warde P, Timilshina N et al (2021) Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. Cancer 127(14):2587–2594CrossRefPubMed Alibhai SMH, Breunis H, Hansen AR, Gregg R, Warde P, Timilshina N et al (2021) Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. Cancer 127(14):2587–2594CrossRefPubMed
28.
Zurück zum Zitat Smith MR, Hussain MHA, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. J Clin Oncol 40(6_suppl):13CrossRef Smith MR, Hussain MHA, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. J Clin Oncol 40(6_suppl):13CrossRef
29.
Zurück zum Zitat de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091–2102CrossRefPubMed de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091–2102CrossRefPubMed
30.
Zurück zum Zitat Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103CrossRefPubMedPubMedCentral Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103CrossRefPubMedPubMedCentral
Metadaten
Titel
Prostatakarzinom beim älteren Mann
Besonderheiten der Diagnostik und Therapie
verfasst von
PD Dr. Stephan Degener
Oliver Schmalz
Marco Tosch
Daniel Gödde
Friedrich-Carl von Rundstedt
Marc D. Piroth
Publikationsdatum
12.06.2023
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 4/2023
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-023-02194-z

Weitere Artikel der Ausgabe 4/2023

Zeitschrift für Gerontologie und Geriatrie 4/2023 Zur Ausgabe

Journal Club

Journal Club

Mitteilungen der DGG

Mitteilungen der DGG

Mitteilungen der ÖGGG

Mitteilungen der ÖGGG